MassIVE MSV000093865

Partial Public PXD048530

Identification by Shotgun Proteomics with Q-Exactive Hybrid Quadripole-Orbitrap High Resolution Tandem Mass-Spectrometry, Histone isoforms’ Hypermethylation Phenotype as A Hallmark Characteristic of Human-IDH-Mutant High-Grade Gliomas

Subscribe Comment Convert Spectra Add Reanalysis

Description

Histone variant-post-translational modifications (PTMs) have been allied to various pathological processes, especially in cancer-onset, envisaged as obvious epigenetic biomarkers-based genotoxicity and as predictors for pathological diagnosis and prognosis. Consequently, their mapping and characterization constitute a critical field of study facilitated by the recent advances in the Mass spectrometry (MS) high-throughput technique, which has emerged as the most powerful tool to achieve insights into chromatin biology and epigenetics. The current study endeavored to the analysis of histone-isoforms’ methylation in neural cells induced by environmental stressors such as pesticides. Our protocol consisted first of a 3D in-vitro developing neurospheroid model derived from human IDH-mutant high-grade gliomas, then treatment by pesticide mixture at the inhibitory concentration IC50. Afterwards, histones were extracted, precipitated, and derivatized by propionylation prior trypsin digestion for analysis by the most popular bottom-up proteomics-based approach using a nano flow-UHPLC coupeled to Q Exactive HF hybrid quadrupole-Orbitrap high resolution tandem mass spectrometry. Raw MS files were searched against human protein database based on the species of the samples using the MAXQUANT software. The ionization was performed in a positive-ion mode and the mass spectrometer was operated in the data-dependent acquisition (DDA) mode. Histone isoforms’ methylation were validated manually by De novo peptide sequencing using the “PEAKS STUDIO” software package, which consisted in comparing the MS/MS spectra of peptide sequences between treated and non-treated spheroids. The results revealed a hypermethylation phenotype in histone isoforms, which is a hallmark characteristic of Isocitrate-Dehydrogenase (IDH)-mutated high-grade gliomas, envisaged as an adaptive strategy adapted by cancer cells to overcome stress and promote invasiveness. [doi:10.25345/C5QB9VH1F] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: Histone Post-Translational Modifications ; Epigenetics ; Neurospheroids ; Tandem Mass Spectrometry ; Genotoxicity ; Biomarkers ; De novo peptide sequencing. ; Histone-isoforms ; High-grade gliomas ; Grade-IV astrocytomas ; Hypermethylation ; Bottom-up proteomic-based approach

Contact

Principal Investigators:
(in alphabetical order) 		Kaouthar Louati, University of Monastir, Faculty of Pharmacy, Laboratory of Chemical, Pharmacological and Galenic Drug Development- LR12ES09, Road Avicenne 5000, Monastir, Tunisia, Tunisie
Submitting User: KAOUTHARLOUATI7

Publications

Kaouthar Louati, Fatma Kolsi, Manel Mellouli, Hanen Louati, Rania Zribi, Rim Kallel, Mahdi Borni, Yassine Gdoura, Leila Sellami Hakim, Amina Maalej, Sirine Choura, Mohamed Chamkha, Sami Sayadi, Basma Mnif, Zouheir Khemakhem, Tahya Sellami Boudawara, Mohamed Zaher Boudawara, Abderrahman Bouraoui, Jamil Kraiem, Fathi Safta.
The Identification by Shotgun Proteomics with High-Resolution Tandem Mass-Spectrometry of Histone Isoforms’ Hypermethylation Phenotype as a Hallmark Characteristic of Human-IDH-Mutant High-Grade Gliomas: Epigenetic Applications for Genotoxicity-Based Biomarkers and Cancer Therapy Targets.
J. Proteome Res. 2025, https://doi.org/10.1021/acs.jproteome.5c00158 ; Published July 18, 2025.

Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

Species

Instrument

Modifications

- Dataset Reanalyses

+ Dataset History

Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.